18-04-2024 | Hemolytic Uremic Syndrome | Editorial Commentary
Managing anti-factor H antibody-associated hemolytic uremic syndrome: time for consensus
Published in: Pediatric Nephrology
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C (2020) Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol 12:295–305CrossRefPubMedPubMedCentral
Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C (2020) Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol 12:295–305CrossRefPubMedPubMedCentral
2.
go back to reference Formeck C, Swiatecka-Urban A (2019) Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 34:1337–1348CrossRefPubMed
Formeck C, Swiatecka-Urban A (2019) Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 34:1337–1348CrossRefPubMed
3.
go back to reference Michael M, Bagga A, Sartain SE, Smith RJH (2022) Haemolytic uraemic syndrome. Lancet 400:1722–1740CrossRefPubMed
Michael M, Bagga A, Sartain SE, Smith RJH (2022) Haemolytic uraemic syndrome. Lancet 400:1722–1740CrossRefPubMed
4.
go back to reference Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommele A, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Fremeaux-Bacchi V; Global aHUS Registry (2018) Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 94:408-418
Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommele A, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Fremeaux-Bacchi V; Global aHUS Registry (2018) Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 94:408-418
5.
go back to reference Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andre JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fremeaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180–2187CrossRefPubMedPubMedCentral
Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andre JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fremeaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180–2187CrossRefPubMedPubMedCentral
6.
go back to reference Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T; German-Austrian HUS Study Group (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407-415
Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T; German-Austrian HUS Study Group (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407-415
7.
go back to reference Jozsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C (2008) Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111:1512–1514CrossRefPubMed
Jozsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C (2008) Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111:1512–1514CrossRefPubMed
8.
go back to reference Shawky S, Safouh H, Gamal M, Abbas MM, Aboul-Enein A, Sawai T, Fahmy Y, Selim H (2021) Anti-factor H antibodies in Egyptian children with hemolytic uremic syndrome. Int J Nephrol 2021:6904858CrossRefPubMedPubMedCentral
Shawky S, Safouh H, Gamal M, Abbas MM, Aboul-Enein A, Sawai T, Fahmy Y, Selim H (2021) Anti-factor H antibodies in Egyptian children with hemolytic uremic syndrome. Int J Nephrol 2021:6904858CrossRefPubMedPubMedCentral
9.
go back to reference Song D, Liu XR, Chen Z, Xiao HJ, Ding J, Sun SZ, Liu HY, Guo WY, Wang SX, Yu F, Zhao MH, Chinese Renal TMA, Institutes N (2017) The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome. Pediatr Nephrol 32:811–822CrossRefPubMed
Song D, Liu XR, Chen Z, Xiao HJ, Ding J, Sun SZ, Liu HY, Guo WY, Wang SX, Yu F, Zhao MH, Chinese Renal TMA, Institutes N (2017) The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome. Pediatr Nephrol 32:811–822CrossRefPubMed
10.
go back to reference Stolbova S, Bezdicka M, Seeman T, Prohaszka Z, Csuka D, Hrachovinova I, Burkert J, Simankova N, Pruhova S, Zieg J (2020) Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children. Eur J Pediatr 179:1739–1750CrossRefPubMed
Stolbova S, Bezdicka M, Seeman T, Prohaszka Z, Csuka D, Hrachovinova I, Burkert J, Simankova N, Pruhova S, Zieg J (2020) Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children. Eur J Pediatr 179:1739–1750CrossRefPubMed
11.
go back to reference Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V; HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15-39
Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V; HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15-39
12.
go back to reference Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, Patriquin CJ, Pham HP, Sanchez AP, Schneiderman J, Witt V, Zantek ND, Dunbar NM (2023) Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the american society for apheresis: the Ninth Special Issue. J Clin Apher 38:77–278
Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, Patriquin CJ, Pham HP, Sanchez AP, Schneiderman J, Witt V, Zantek ND, Dunbar NM (2023) Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the american society for apheresis: the Ninth Special Issue. J Clin Apher 38:77–278
13.
go back to reference Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D (2017) Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 92:1261–1271CrossRefPubMedPubMedCentral
Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D (2017) Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 92:1261–1271CrossRefPubMedPubMedCentral
14.
go back to reference Hofer J, Riedl Khursigara M, Perl M, Giner T, Rosales A, Cortina G, Waldegger S, Jungraithmayr T, Wurzner R (2021) Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS. Pediatr Nephrol 36:917–925CrossRefPubMed
Hofer J, Riedl Khursigara M, Perl M, Giner T, Rosales A, Cortina G, Waldegger S, Jungraithmayr T, Wurzner R (2021) Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS. Pediatr Nephrol 36:917–925CrossRefPubMed
15.
go back to reference Ferri M, Zotta M, Donadelli R, Dossier C, Duneton C, El-Sissy C, Fremeau-Bacchi V, Kwon T, Quadri L, Pasini A, Sellier-Leclerc A, Vivarelli M, Hogan J (2024) Anti CFH-associated hemolytic uremic syndrome: do we still need plasma exchange? Pediatr Nephrol. https://doi.org/10.1007/s00467-024-06373-x
Ferri M, Zotta M, Donadelli R, Dossier C, Duneton C, El-Sissy C, Fremeau-Bacchi V, Kwon T, Quadri L, Pasini A, Sellier-Leclerc A, Vivarelli M, Hogan J (2024) Anti CFH-associated hemolytic uremic syndrome: do we still need plasma exchange? Pediatr Nephrol. https://doi.org/10.1007/s00467-024-06373-x
16.
go back to reference Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R (2018) Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial 22:178–188CrossRefPubMed
Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R (2018) Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial 22:178–188CrossRefPubMed
17.
go back to reference Matrat L, Bacchetta J, Ranchin B, Tanne C, Sellier-Leclerc AL (2021) Pediatric atypical hemolytic-uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil? Pediatr Nephrol 36:1647–1650CrossRefPubMed
Matrat L, Bacchetta J, Ranchin B, Tanne C, Sellier-Leclerc AL (2021) Pediatric atypical hemolytic-uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil? Pediatr Nephrol 36:1647–1650CrossRefPubMed
18.
go back to reference Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, Wada H, Uchida Y, Kokame K, Matsumoto M, Fujimura Y, Miyata T, Nangaku M (2018) Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 22:1088–1099CrossRefPubMedPubMedCentral
Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, Wada H, Uchida Y, Kokame K, Matsumoto M, Fujimura Y, Miyata T, Nangaku M (2018) Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 22:1088–1099CrossRefPubMedPubMedCentral
19.
go back to reference Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provot F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Chatelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Fremeaux-Bacchi V (2021) Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 137:2438–2449CrossRefPubMed
Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provot F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Chatelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Fremeaux-Bacchi V (2021) Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 137:2438–2449CrossRefPubMed
20.
go back to reference Fakhouri F, Schwotzer N, Frémeaux-Bacchi V (2023) How I diagnose and treat atypical hemolytic uremic syndrome. Blood 141:984–995CrossRefPubMed
Fakhouri F, Schwotzer N, Frémeaux-Bacchi V (2023) How I diagnose and treat atypical hemolytic uremic syndrome. Blood 141:984–995CrossRefPubMed
21.
go back to reference Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A (2019) Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database. Front Immunol 10:1282CrossRefPubMedPubMedCentral
Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A (2019) Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database. Front Immunol 10:1282CrossRefPubMedPubMedCentral
22.
go back to reference Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M (2019) Rare functional variants in complement genes and anti-FH autoantibodies-associated aHUS. Front Immunol 10:853CrossRefPubMedPubMedCentral
Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M (2019) Rare functional variants in complement genes and anti-FH autoantibodies-associated aHUS. Front Immunol 10:853CrossRefPubMedPubMedCentral
23.
go back to reference Durey MA, Sinha A, Togarsimalemath SK, Bagga A (2016) Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 12:563–578CrossRefPubMed
Durey MA, Sinha A, Togarsimalemath SK, Bagga A (2016) Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 12:563–578CrossRefPubMed
24.
go back to reference Khandelwal P, Thomas CC, Rathi BS, Hari P, Tiwari AN, Sinha A, Bagga A (2019) Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: audit of efficacy and safety. J Clin Apher 34:555–562CrossRefPubMed
Khandelwal P, Thomas CC, Rathi BS, Hari P, Tiwari AN, Sinha A, Bagga A (2019) Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: audit of efficacy and safety. J Clin Apher 34:555–562CrossRefPubMed
25.
go back to reference Berentsen S, Hill A, Hill QA, Tvedt THA, Michel M (2019) Novel insights into the treatment of complement-mediated hemolytic anemias. Ther Adv Hematol 10:2040620719873321CrossRefPubMedPubMedCentral
Berentsen S, Hill A, Hill QA, Tvedt THA, Michel M (2019) Novel insights into the treatment of complement-mediated hemolytic anemias. Ther Adv Hematol 10:2040620719873321CrossRefPubMedPubMedCentral
26.
go back to reference Khandelwal P, Joshi A, Mathur A, Puraswani M, Gurjar BS, Sinha A, Hari P, Faruq M, Bagga A (2023) Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 38:2659–2668CrossRefPubMed
Khandelwal P, Joshi A, Mathur A, Puraswani M, Gurjar BS, Sinha A, Hari P, Faruq M, Bagga A (2023) Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 38:2659–2668CrossRefPubMed
Metadata
- Title
- Managing anti-factor H antibody-associated hemolytic uremic syndrome: time for consensus
- Authors
-
Priyanka Khandelwal
Arvind Bagga
- Publication date
- 18-04-2024
- Publisher
- Springer Berlin Heidelberg
- Keyword
- Hemolytic Uremic Syndrome
- Published in
-
Pediatric Nephrology
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X - DOI
- https://doi.org/10.1007/s00467-024-06374-w